Fibulins 3 and 5 antagonize tumor angiogenesis in vivo

被引:152
作者
Albig, AR [1 ]
Neil, JR [1 ]
Schiemann, WP [1 ]
机构
[1] Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA
关键词
D O I
10.1158/0008-5472.CAN-04-4096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lethal tumor growth and progression cannot occur without angiogenesis, which facilitates cancer cell proliferation, survival, and dissemination. Fibulins (FBLN) 5 and 3 are widely expressed extracellular matrix proteins that regulate cell proliferation in a context-specific manner. Reduced FBLN-5 expression has been associated with cancer formation and progression in humans, whereas its constitutive expression antagonizes endothelial cell angiogenic sprouting in vitro. Thus, FBLN-5 may suppress tumorigeriesis by preventing tumor angiogenesis. FBLN-3 is homologous to FBLN-5 and expressed in endothelial cells, yet its role in tumorigenesis and angiogenesis is unknown. We find FBLN-3 expression to be altered in some human tumors and that its constitutive expression in endothelial cells inhibited their proliferation, invasion, and angiogenic sprouting, as well as their response to vascular endothelial growth factor as measured by p38 mitogen-activated protein kinase activation. In endothelial cells, both FBLNs (a) reduced angiogenic sprouting stimulated by basic fibroblast growth factor (bFGF); (b) inhibited matrix metalloproteinase expression and activity; and (c) stimulated tissue inhibitor of metalloproteinase expression. More importantly, both FBLNs prevented angiogenesis and vessel infiltration into bFGF-supplemented Matrigel plugs implanted in genetically normal mice, as well as decreased the growth and blood vessel density in tumors produced by MCA102 fibrosarcoma cells implanted s.c. into syngeneic mice. Our findings establish FBLN-3 and FBLN-5 as novel angiostatic agents capable of reducing tumor angiogenesis and, consequently, tumor growth in vivo and suggest that these angiostatic activities may one day be exploited to combat tumor angiogenesis and metastasis in cancer patients.
引用
收藏
页码:2621 / 2629
页数:9
相关论文
共 40 条
[11]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[12]   Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4 [J].
Giltay, R ;
Timpl, R ;
Kostka, G .
MATRIX BIOLOGY, 1999, 18 (05) :469-480
[13]  
Guo NH, 1997, CANCER RES, V57, P1735
[14]   Structure and chromosomal assignment of the human S1-5 gene (FBNL) that is highly homologous to fibrillin [J].
Ikegawa, S ;
Toda, T ;
Okui, K ;
Nakamura, Y .
GENOMICS, 1996, 35 (03) :590-592
[15]   Clinical translation of angiogenesis inhibitors [J].
Kerbel, R ;
Folkman, J .
NATURE REVIEWS CANCER, 2002, 2 (10) :727-739
[16]   Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) - Implications for macular degenerations [J].
Klenotic, PA ;
Munier, FL ;
Marmorstein, LY ;
Anand-Apte, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (29) :30469-30473
[17]   Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice [J].
Kostka, G ;
Giltay, R ;
Bloch, W ;
Addicks, K ;
Timpl, R ;
Fässler, R ;
Chu, ML .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (20) :7025-7034
[18]   EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature [J].
Kowal, RC ;
Richardson, JA ;
Miano, JM ;
Olson, EN .
CIRCULATION RESEARCH, 1999, 84 (10) :1166-1176
[19]  
Langton KP, 2000, J BIOL CHEM, V275, P27027
[20]   AN OVEREXPRESSED GENE TRANSCRIPT IN SENESCENT AND QUIESCENT HUMAN FIBROBLASTS ENCODING A NOVEL PROTEIN IN THE EPIDERMAL GROWTH FACTOR-LIKE REPEAT FAMILY STIMULATES DNA-SYNTHESIS [J].
LECKACZERNIK, B ;
LUMPKIN, CK ;
GOLDSTEIN, S .
MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (01) :120-128